non-Hodgkin lymphoma

CAR T-cell therapies in treating lymphoma: Pros and consCatherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Game-changing gene therapies present cost problems for health execsCAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.
Four ways health execs can prep for costly CAR-T cell therapiesWith the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.
Personalized strategies critical for childhood cancerNext-generation gene sequencing and other advanced technologies for personalized medicine may soon identify biomarkers that will improve treatment response and long-term toxicity risks for childhood cancer patients.
Waldenstrom’s drug shows sustained benefit at 2 yearsIbrutinib, a newly approved drug for Waldenstrom’s Macroglobulinemia, a rare form of lymphoma, continued to control the rare blood cancer, with 95% of patients surviving for 2 years, according to a new study, published in The New England Journal of Medicine.
FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphomaFDA has approved expanded use of ibrutinib for the treatment of Waldenstroms Macroglobulinemia.
FDA approves bortezomib for injection for previously untreated patients with mantle cell lymphomaFDA approved bortezomib (Velcade, Millennium: The Takeda Oncology Company) for injection for use in previously untreated patients with mantle cell lymphoma (MCL), making it the first treatment in the United States to be approved for previously untreated patients with MCL.
FDA drug approvals-August 2014FDA actions in brief, complete response, fast-track designation, priority review, orphan drug designations, first-time generic approval
FDA drug approvals-July 2014FDA drug approvals, priority review, breakthrough designation, fast-track designations, orphan drug designations, first-time generic approval